Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41591-020-0949-6 http://scihub22266oqcxt.onion/10.1038/s41591-020-0949-6 32504052!ä!32504052 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nat+Med 2020 ; 26 (8): 1193-1195 Nephropedia Template TP {{tp|p=32504052|t=2020. Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China |pdf=|usr=}}{{32504052}} gab.com Text Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China JO: Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=32504052 #FOAvip Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection. Twit Text FOAVip Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China ????Nat Med http://www.kidney.de/pget.php?&tw=1&pmid=32504052 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32504052 #FOAvip English Wikipedia <ref>{{Cite pmid|32504052}}</ref> Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China #MMPMID32504052 Xu X; Sun J; Nie S; Li H; Kong Y; Liang M; Hou J; Huang X; Li D; Ma T; Peng J; Gao S; Shao Y; Zhu H; Lau JY; Wang G; Xie C; Jiang L; Huang A; Yang Z; Zhang K; Hou FF Nat Med 2020[Aug]; 26 (8): 1193-1195 PMID32504052show ga Detection of asymptomatic or subclinical novel human coronavirus SARS-CoV-2 infection is critical for understanding the overall prevalence and infection potential of COVID-19. To estimate the cumulative prevalence of SARS-CoV-2 infection in China, we evaluated the host serologic response, measured by the levels of immunoglobulins M and G in 17,368 individuals, in the city of Wuhan, the epicenter of the COVID-19 pandemic in China, and geographic regions in the country, during the period from 9 March 2020 to 10 April 2020. In our cohorts, the seropositivity in Wuhan varied between 3.2% and 3.8% in different subcohorts. Seroposivity progressively decreased in other cities as the distance to the epicenter increased. Patients who visited a hospital for maintenance hemodialysis and healthcare workers also had a higher seroprevalence of 3.3% (51 of 1,542, 2.5-4.3%, 95% confidence interval (CI)) and 1.8% (81 of 4,384, 1.5-2.3%, 95% CI), respectively. More studies are needed to determine whether these results are generalizable to other populations and geographic locations, as well as to determine at what rate seroprevalence is increasing with the progress of the COVID-19 pandemic. Serologic surveillance has the potential to provide a more faithful cumulative viral attack rate for the first season of this novel SARS-CoV-2 infection. |Antibodies, Viral/*blood/immunology[MESH] |Betacoronavirus/pathogenicity[MESH] |COVID-19[MESH] |China/epidemiology[MESH] |Coronavirus Infections/*blood/epidemiology/virology[MESH] |Female[MESH] |Health Personnel[MESH] |Humans[MESH] |Immunoglobulin G/*blood/immunology[MESH] |Immunoglobulin M/*blood/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/*blood/epidemiology/virology[MESH] |SARS-CoV-2[MESH]Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2(epmc).pdf DeepDyve Pubget Overpricing